Legal Representation
Attorney
Diane J. Mason
USPTO Deadlines
Next Deadline
1296 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20230801)
Due Date
August 01, 2029
Grace Period Ends
February 01, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
26 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 27, 2023 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Nov 10, 2023 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Nov 2, 2023 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Nov 1, 2023 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Nov 1, 2023 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Aug 1, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Aug 1, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| May 17, 2023 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| May 16, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 16, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 26, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Apr 26, 2023 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Apr 26, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 13, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 20, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 17, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 17, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 1, 2023 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jan 12, 2023 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jan 12, 2023 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Nov 2, 2022 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Nov 1, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 28, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 22, 2022 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Mar 18, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 17, 2022 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical agents affecting digestive organs; medicines for treating intestinal disorders; Pharmaceutical preparations in the nature of proton-pump inhibitors for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; medicines for the treatment of gastrointestinal diseases; medicines for human purposes for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; pharmaceutical preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection; ethical medicinal preparations for the treatment of gastroesophageal reflux disease, peptic ulcer, intestinal disorders, gastrointestinal disorders, erosive esophagitis, gastritis, gastric ulcer, duodenal ulcer, non-erosive reflux disease, duodenal ulcer recurrence and pathological hypersecretory conditions including Zollinger-Ellison syndrome and combination antibiotic therapy for the treatment of Helicobacter pylori infection
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the stylized wording "FEXUCLUE" in blue, wherein the inside of the letter "C" is a design of the stomach in the colors red, orange, yellow and green. The color white in the mark is background only and is not claimed as a feature of the mark.
Color Claim
The color(s) the colors blue, green, red, orange, and yellow are claimed as features of the mark is/are claimed as a feature of the mark.
Classification
International Classes
005